Contributors
Michael W. Bolt(Vertex Pharmaceuticals (United States)), Jayanthi Wolf, Alexandra Capela, Eric B. Harstad(Pfizer (United States)), Jacqueline Brassard(21c Consultancy (United Kingdom)), Marque D. Todd, Ping Peng(Central South University), Eloïse Hudry(Novartis (Switzerland)), Padma Kumar Narayanan(Wave Life Sciences (United States)), Maggie Dempster(GlaxoSmithKline (United States)), Gautham K. Rao(Bristol-Myers Squibb (United States)), Justine J. Cunningham(Regenxbio (United States)), Catherine Priest, Lisa M. Plitnick, Anu Connor(Ipsen (United States)), Christina L. Zuch de Zafra(Pfizer (United States)), Karin Staflin, Donna W. Lee(Impact Assessment), Rodney A. Prell, Manish Gupta(Genmab (United States)), Sieto Bosgra(Genmab (Netherlands)), Claudette L. Fuller(United States Army Medical Research Institute of Infectious Diseases), Amy Kim, Deborah L. Novicki, Karen Price(Purchase College), Eugene P. Brandon(IQVIA (United States)), Wendy Halpern(Roche (Switzerland)), Chandrashekhar K. Korgaonkar(Regeneron (United States)), Anna Dahlman(Genmab (United States))
Cited by 0
Related Papers
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
|Nature Biotechnology|2008|1.4k
The Major Risk Factors for Alzheimer’s Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques
|Cell Reports|2019|978
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Amyloid β Induces the Morphological Neurodegenerative Triad of Spine Loss, Dendritic Simplification, and Neuritic Dystrophies through Calcineurin Activation
|Journal of Neuroscience|2010|371
Cancer Drug Discovery and Development
|Humana Press eBooks|2003|194